GRIN Therapeutics Announces First Patient Dosed in Global Phase 3 Beeline Trial of Investigational Radiprodil for GRIN-Related Neurodevelopmental Disorder

/PRNewswire/ — GRIN Therapeutics, Inc., a leader in the development of targeted disease-specific therapies for serious neurodevelopmental disorders, today…Read More